Jun. 30 at 8:03 PM
$PRME saw a newly granted patent (US 12,668,814 B2) from the Broad Institute covering engineered muscle-targeting AAV capsids (“MyoAAV”), designed for improved muscle specificity with reduced liver tropism and higher delivery potency.
The technology, developed by Sabeti, Tabebordbar, and Wagers, sits within a broader ecosystem of gene-editing and delivery innovations. While existing exclusive licensing arrangements (including Sarepta in certain neuromuscular indications) may constrain some applications, Broad Institute licensing is often field-structured rather than universally exclusive.
